Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose Escalation and Dose-Expansion Study (vol 35, pg 157, 2017)

被引：0
|
作者：
Burris, Howard A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 358
页数：1
相关论文
共 50 条
  • [1] Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study (vol 35, pg 157, 2017)
    Nogova
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) : 926 - 926
  • [2] Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
    Nogova, Lucia
    Sequist, Lecia V.
    Garcia, Jose Manuel Perez
    Andre, Fabrice
    Delord, Jean-Pierre
    Hidalgo, Manuel
    Schellens, Jan H. M.
    Cassier, Philippe A.
    Camidge, D. Ross
    Schuler, Martin
    Vaishampayan, Ulka
    Burris, Howard
    Tian, G. Gary
    Campone, Mario
    Wainberg, Zev A.
    Lim, Wan-Teck
    LoRusso, Patricia
    Shapiro, Geoffrey I.
    Parker, Katie
    Chen, Xueying
    Choudhury, Somesh
    Ringeisen, Francois
    Graus-Porta, Diana
    Porter, Dale
    Isaacs, Randi
    Buettner, Reinhard
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 157 - +
  • [3] Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
    Pal, Sumanta K.
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean H.
    Berger, Raanan
    Quinn, David I.
    Galsky, Matthew D.
    Wolf, Juergen
    Dittrich, Christian
    Keam, Bhumsuk
    Delord, Jean-Pierre
    Schellens, Jan H. M.
    Gravis, Gwenaelle
    Medioni, Jacques
    Maroto, Pablo
    Sriuranpong, Virote
    Charoentum, Chaiyut
    Burris, Howard A.
    Grunwald, Viktor
    Petrylak, Daniel
    Vaishampayan, Ulka
    Gez, Eliahu
    De Giorgi, Ugo
    Lee, Jae-Lyun
    Voortman, Jens
    Gupta, Sumati
    Sharma, Sunil
    Mortazavi, Amir
    Vaughn, David J.
    Isaacs, Randi
    Parker, Katie
    Chen, Xueying
    Yu, Kun
    Porter, Dale
    Porta, Diana Graus
    Bajorin, Dean F.
    CANCER DISCOVERY, 2018, 8 (07) : 812 - 821
  • [4] Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma
    Lyou, Yung
    Grivas, Petros
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean
    Quinn, David, I
    Petrylak, Daniel P.
    Galsky, Matthew
    Vaishampayan, Ulka
    De Giorgi, Ugo
    Gupta, Sumati
    Burris, Howard
    Rearden, Jessica
    Li, Ai
    Wang, Hao
    Reyes, Maribel
    Moran, Susan
    Daneshmand, Siamak
    Bajorin, Dean
    Pal, Sumanta K.
    EUROPEAN UROLOGY, 2020, 78 (06) : 916 - 924
  • [5] Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations
    Pal, Sumanta K.
    Rosenberg, Jonathan E.
    Keam, Bhumsuk
    Wolf, Juergen
    Berger, Raanan
    Dittrich, Christian
    Hoffman-Censits, Jean H.
    Quinn, David
    van der Noll, Ruud
    Burris, Howard A.
    Galsky, Matt D.
    Gravis, Gwenaelle
    Lee, Jae-Lyun
    Medioni, Jacques
    Mortazavi, Amir
    Maroto, Pablo
    Parker, Katie
    Chen, Xueying
    Isaacs, Randi
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
    Tabernero, Josep
    Bahleda, Rastislav
    Dienstmann, Rodrigo
    Infante, Jeffrey R.
    Mita, Alain
    Italiano, Antoine
    Calvo, Emiliano
    Moreno, Victor
    Adamo, Barbara
    Gazzah, Anas
    Zhong, Bob
    Platero, Suso J.
    Smit, Johan W.
    Stuyckens, Kim
    Chatterjee-Kishore, Moitreyee
    Rodon, Jordi
    Peddareddigari, Vijay
    Luo, Feng R.
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3401 - +
  • [7] Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Andre, Fabrice
    Ranson, Malcolm
    Dean, Emma
    Varga, Andrea
    van der Noll, Ruud
    Stockman, Paul K.
    Ghiorghiu, Dana
    Kilgour, Elaine
    Smith, Paul D.
    Macpherson, Merran
    Lawrence, Peter
    Hastie, Andrew
    Schellens, Jan H. M.
    CANCER RESEARCH, 2013, 73 (08)
  • [8] Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Shitara, Kohei
    Kojima, Takashi
    Kuboki, Yasutoshi
    Matsubara, Nobuaki
    Bando, Hideaki
    Yoh, Kiyotaka
    Naito, Yoichi
    Hirai, Hiroshi
    Kurokawa, Yukinori
    Kato, Terufumi
    Morizane, Chigusa
    CANCER SCIENCE, 2023, 114 (02) : 574 - 585
  • [9] Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
    Deng, Ting
    Zhang, Le
    Shi, Yehui
    Bai, Guiying
    Pan, Yueyin
    Shen, Aizong
    Han, Xinghua
    Yang, Zhaoyi
    Chen, Mingxia
    Zhou, Hui
    Luo, Yang
    Zheng, Shirui
    Ba, Yi
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 808 - 815
  • [10] Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors
    Eskens, Ferry A. L. M.
    Steeghs, Neeltje
    Verweij, Jaap
    Bloem, Johan L.
    Christensen, Olaf
    van Doorn, Leni
    Ouwerkerk, Jan
    de Jonge, Maja J. A.
    Nortier, Johan W. R.
    Kraetzschmar, Joern
    Rajagopalan, Prabhu
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4169 - 4176
12345